scispace - formally typeset
B

Barry Iacopetta

Researcher at University of Western Australia

Publications -  190
Citations -  14545

Barry Iacopetta is an academic researcher from University of Western Australia. The author has contributed to research in topics: Colorectal cancer & Microsatellite instability. The author has an hindex of 64, co-authored 190 publications receiving 13770 citations. Previous affiliations of Barry Iacopetta include University of Palermo & Council on Education for Public Health.

Papers
More filters
Journal ArticleDOI

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

TL;DR: The inclusion of FOXP3(+) Treg density in normal and tumor tissue had stronger prognostic significance in colorectal cancer compared with CD8(+) and CD45RO(+) lymphocytes, and may help to improve the prognostication of early-stage coloreCTal cancer.
Journal ArticleDOI

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

H J N Andreyev, +82 more
TL;DR: In this paper, the effect of the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer was investigated using a multivariate analysis.
Journal ArticleDOI

Are there two sides to colorectal cancer

TL;DR: Differences between normal right and left colonic segments that could favour progression through different tumourigenic pathways are summarized in this review and the existence of 2 broadly different groups of cancer defined by site of origin in the colon should be considered.
Journal ArticleDOI

Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR.

TL;DR: It is proposed that using a pentaplex polymerase chain reaction system allows accurate evaluation of tumor MSI status of DNA with 100% sensitivity and specificity without the need to match normal DNA.
Journal ArticleDOI

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer

TL;DR: The survival benefits seen in patients treated with adjuvant chemotherapy suggest that data from previous trials of adjUvant chemotherapy should be reassessed and the predictive value of MSI status confirmed.